Time-window of early detection of response to concurrent chemoradiation in cervical cancer by using diffusion-weighted M
- PDF / 1,724,263 Bytes
- 8 Pages / 595.276 x 793.701 pts Page_size
- 43 Downloads / 133 Views
RESEARCH
Open Access
Time-window of early detection of response to concurrent chemoradiation in cervical cancer by using diffusion-weighted MR imaging: a pilot study Ying Liu1, Haoran Sun2, Renju Bai2 and Zhaoxiang Ye1*
Abstract Background: To investigate the feasibility of DWI in evaluating early therapeutic response of uterine cervical cancer to concurrent chemoradiation (CCR) and establish optimal time window for early detection of treatment response. Methods: This was a prospective study and informed consent was obtained from all patients. Thirty-three patients with uterine cervical cancer who received CCR underwent conventional MRI and DWI examinations prior to therapy (base-line) and at 3 days (postT1), 7 days (postT2), 14 days (postT3), 1 month (postT4) and 2 months (postT5) after the therapy initiated. Tumor response was determined by comparing the base-line and postT5 MRI by using RECIST criterion. Results: Percentage ADC change (γADC) of complete response (CR) group at each follow up time was greater than that of partial response (PR) group, and the differences were significant at postT3 (p = 0.007), postT4 (p = 0.001), and postT5 (p = 0.019). There was positive correlation between γADC at each follow-up time and percentage size reduction at postT5. The day of 14 after the therapy initiated can be considered as the optimal time for monitoring early treatment response of uterine cervical cancer to CCR, and the representative and sensitive index was γADC. With the cut-off value of 35.4 %, the sensitivity and specificity for prediction of CR group were 100 % and 73.1 %, respectively. Conclusions: It is feasible to use DWI to predict and monitor early treatment response in patients with uterine cervical cancer that undergoing CCR, and optimal time window for early detection of tumor response is the day of 14 after therapy initiated.
Background Uterine cervical cancer remains to be the second most prevalent gynaecological tumors worldwide [1]. Recently, cisplatin-based concurrent chemoradiation (CCR) has been established as being more effective than radiation therapy (RT) alone because chemotherapy has been shown to increase the sensitivity of tumor cells to radiation and to control both local and systemic disease manifestations [2]. However, not all tumors of the same pathological type and FIGO stage will follow the same course of disease; individual responses to CCR have been * Correspondence: [email protected] 1 Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China Full list of author information is available at the end of the article
shown to vary significantly. Therefore, precise assessing tumor response before or at an early stage of CCR is important for treatment planning and for determining the prognosis. Tumor response to therapy is conventionally assessed by changes in tumor size according to the Response Evaluation Criteria in Solid Tumors (RECIST) using co
Data Loading...
